Skip to main
ZURA

ZURA Stock Forecast & Price Target

ZURA Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Zura Bio is well positioned for success with its strong focus on developing innovative treatments for chronic and debilitating autoimmune and inflammatory diseases with high unmet need. The company's in-licensed pipeline candidates, such as ZB-106 and ZB-168, show promising results in early clinical trials, and the company has an experienced leadership team with a successful track record in the biotech industry. While there are risks associated with biotech investments, the potential for success in Zura's pipeline and the company's commitment to addressing unmet medical needs make it an attractive investment opportunity.

Bears say

Zura Bio is a clinical-stage biotechnology company developing novel medicines for autoimmune and inflammatory diseases with unmet medical need. However, the company faces multiple risks, including regulatory and commercial risks, clinical risks, financing risks, and intellectual property risks, which could hinder the approval and commercialization of its pipeline candidates. The company's stock price may also experience volatility due to market fluctuations and the inherent risk of investing in biotechnology companies. Additionally, there is a lack of proven efficacy for IL-17A inhibitors in relation to SSc, and competition in the market from other therapies targeting similar indications could impact market penetration and pricing. As a result, the financial analyst has a negative outlook on Zura Bio's stock.

ZURA has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zura Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zura Bio Ltd (ZURA) Forecast

Analysts have given ZURA a Buy based on their latest research and market trends.

According to 5 analysts, ZURA has a Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zura Bio Ltd (ZURA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.